Buddy Roemer: Me, O...
Health Care: Drugs
Telik Inc. (TELK: NASDAQ)
$0.18 0.00 | 0.06%
02/08/12 - 04:00 PM ET
652.43K / 281.80K
Vol / Avg. Vol:0.18 / 0.18
Open / Prev. Close:0.17 - 0.18
Today's Range:0.16 - 1.25
52 Wk Range:-9.09%
Performance YTD:TheStreet Rating:
Portfolios with TELK
- Portfolio NameUser Type
- ContributorBarron's Insider Purchases ...
- UserASCO 2010
- UserASCO 2009 Nymph's Watch List.
- UserPeter J. Lotti Portfolio 1
- UserPete'spicks
- ContributorBarron's Activist Stocks 11...
- ContributorBarron's Activist Stocks 11...
- UserC070707
- Usergonzomoney
- UserPART 9 JPMorgan 26th Annual...
Latest TELK Headlines from TheStreet
- Icahn Should Hang It Up: Activist 10.28.09 | 06:10 am
- Insider Sells $20.2 Million of National Semi 01.16.09 | 09:01 am
- Insider Sells $1.2M of Noven Pharmaceuticals 01.06.09 | 09:01 am
- Feuerstein's Biotech-Stock Mailbag 04.05.08 | 11:04 am
- Feuerstein's Biotech-Stock Mailbag 11.03.07 | 11:11 am
- Monday's Health Winners & Losers 10.15.07 | 04:10 pm
- Feuerstein's Biotech-Stock Mailbag 09.29.07 | 11:09 am
- Telik Fails Ethics Test 08.09.07 | 08:08 am
- These Homebuilder Stocks Could Soar 07.13.07 | 08:07 am
- Stockpickr: How to Trade Like Carl Icahn 06.20.07 | 12:06 am
Press Releases for TELK
- Telik Announces Presentation And Webcast At 14th Annual BIO CEO & Investor Conference - PR Newswire 02.08.12 | 09:02 am
- Telik Announces Presentation And Webcast At 5th Annual OneMedForum Conference - PR Newswire 01.04.12 | 09:01 am
- Telik Announces The Results Of Genetic Signature Studies Of Myelodysplastic Syndrome Patients Likely To Respond To Telintra® (Ezatiostat Hydrochloride, TLK199) At The Annual Meeting Of The American Society Of Hematology - PR Newswire 12.13.11 | 09:12 am
- Telik Announces Phase 1 Results Of A Multicenter Study Of Telintra® (Ezatiostat Hydrochloride, TLK199) In Combination With Revlimid® (Lenalidomide) In Patients With Myelodysplastic Syndrome - PR Newswire 12.13.11 | 09:12 am
- Telik Announces Telintra Clinical Presentations At The Annual Meeting Of The American Society Of Hematology - PR Newswire 11.10.11 | 09:11 am
- Telik Announces Publication Of A Report Of Complete Response Of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment With Telintra® - PR Newswire 11.03.11 | 09:11 am
- Telik Announces Initiation Of A Phase 2b Clinical Trial Of Telintra® (Ezatiostat HCL) In Patients With Low To Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome - PR Newswire 10.13.11 | 09:10 am
- Telik Announces Publication In The Journal Cancer Of A Phase 2 Randomized Multicenter Study Of Two Extended Dosing Schedules Of Oral Ezatiostat In Low To Intermediate-1 Risk Myelodysplastic Syndrome - PR Newswire 09.29.11 | 09:09 am
- Telik Announces Initiation Of A Phase 2 Clinical Trial Of Telintra® (Ezatiostat HCl) In Patients With Revlimid® Refractory Or Resistant Deletion 5q Myelodysplastic Syndrome - PR Newswire 06.07.11 | 04:06 pm
- Telik Announces Presentation Of New Data On The Characterization Of Novel Ezatiostat (TELINTRA®, TLK199) Analogs At American Association For Cancer Research Annual Meeting - PR Newswire 04.05.11 | 08:04 am
Partner Headlines for TELK
- 19 High Growth Micro Cap Stocks Under $10 - Seeking Alpha 01.23.11 | 07:01 am
